Abstract
Cancer is one of the biggest health problems of contemporary humanity, representing the second cause of death after cardiovascular diseases, caused by many contributing factors, such as population growth, ageing, stress, pollution, unhealthy diet, tumor diversity and heterogenity, difficulties in correct and early diagnosis and inefficiency of current treatments (e.g. cytoreduction, chemotherapy, radiotherapy, etc.). This leads us to look for new ways of dealing with cancer, such as immunotherapy and personalized therapy, which consider the type of tumour, mutations and expression levels of certain genes, making it necessary to detect specific markers. A category of such specific markers is represented by the proteins involved in inter- and intra-cellular signaling which play essential roles in tumor transformation, progression and dissemination. In cancer, some canonical signaling pathways, including RAS-RAF-MEK-ERK, P13K-PKB/AKT, JAK-STAT, HIF1-VEGF, TGFB, NOTCH, RAP1, TP53, B-catenin/WNT, HIPPO, KEAP-NRF2, MYC and CDKN2 (cell cycle), may be dysregulated. In this review, we detail the roles of RAS–RAF–MEK–ERK signaling pathway in tumorigenic processes and the types of abnormalities that affect them in cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.